Navigation Links
Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer
Date:9/8/2011

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor. In an article published online September 8, 2011 in the Journal of the National Cancer Institute, RTOG researchers report that treating patients with concurrent chemotherapy and radiation therapy significantly increased five‑year survival rates compared with treating patients with radiation therapy upon completion of chemotherapy treatment.

"The significant increase in five-year survival for patients receiving concurrent versus sequential treatment establishes a new treatment standard for this large population of lung cancer patients," says Walter J. Curran, Jr., M.D., RTOG Group Chair, the trial's principal investigator and Executive Director of the Winship Cancer Institute of Emory University in Atlanta. "It is likely the chemotherapy makes the tumor cells more sensitive to radiation therapy, which contributed to the improved long-term patient benefit seen with concurrent therapy," adds Curran.

A total of 610 study participants at 153 institutions across North America were enrolled into the phase III trial and were randomized to receive cisplatin-based chemotherapy in addition to radiation therapy administered sequentially (arm 1), once daily concurrently (arm 2) or twice daily concurrently (arm 3). The percentages of study participants confirmed still living at five years post-treatment in study arms 1, 2 and 3 were 10 percent, 16 percent and 13 percent, respectively. "The significant survival benefit of concurrent treatment confirms the promising results observed in a similar RTOG phase II trial and corroborates the results of a 314-patient Japanese trial and several smaller European trials," says Jeffrey D. Bradley, M.D., Director of the S. Lee Kling Center for Proton Therapy at the Siteman Cancer Center, Washington University School of Medicine in St Louis and RTOG Lung Cancer Committee Chair. "The survival gain related to concurrent treatment was most prominent in arm 2 for which the only difference in treatment compared with arm 1 was the timing of the radiation therapy delivery."

The authors also report that study participants experienced significantly worse side effects with concurrent therapy versus sequential therapy, particularly, severe esophagitis (inflammation of the esophagus lining). However, data collected from study participants, who were followed for a median of 11 years after treatment show that late side effects occurring months or years after treatment were minimal and similar across the three study arms.

Medical oncologist Corey J. Langer, M.D, Director of Thoracic Oncology at the Abramson Cancer Center, University of Pennsylvania in Philadelphia and research co-author states, "Many patients initially diagnosed with inoperable stage III disease are too ill to tolerate the more aggressive concurrent therapy administered in this trial. We are encouraged, however, that new radiation therapy techniques and chemotherapy drugs developed since the trial's conductsome currently under investigationhave the potential to increase the benefit of concurrent therapy. It is critical for RTOG and other groups to continue their investigation of new treatments to improve cancer survival and minimize treatment side effects."


'/>"/>

Contact: Heather Curry
PR@acr.org
703-390-9822
American College of Radiology
Source:Eurekalert

Related medicine news :

1. New study introduces the prospect for concurrent antiangiogenic/antitumorigenic therapy
2. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
3. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
4. Scientists identify microRNA as possible cause of chemotherapy resistance
5. Study evaluates costs and benefits of new chemotherapy drugs
6. Older Colon Cancer Patients Less Likely to Get Chemo
7. Are New Chemo Treatments Cost-Effective?
8. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
9. Researchers find new chemotherapy combination shows promise in endometrial cancer
10. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
11. Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 18, 2017 , ... The CHP suggests that California drivers can avoid hydroplaning ... down and increasing the space between themselves and other vehicles, according to a January ... Raymond R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving ...
(Date:1/19/2017)... Norwalk, CT (PRWEB) , ... January 19, 2017 , ... ... Dr. Sang H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings ... skincare center . , “It is with considerable pleasure to welcome back Dr. Kim ...
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... Seabrook, NH (PRWEB) , ... January 19, 2017 , ... ... develop its business plan and implement new sales and marketing strategies. Grover comes with ... spent the last 5 and a half years as Executive Vice President of Direct ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the American Osteopathic College of Proctology) announced today the opening of 3 ... California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly Hills), Hemorrhoids ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
Breaking Medicine Technology: